Cite

HARVARD Citation

    VanderWalde, A. et al. (n.d.). Activity and safety of ipatasertib (ipat) for AKT activating mutation and/ or PTEN loss/loss of function solid tumors from MyTACTIC. European journal of cancer. pp. S71-. [Online]. 
  
Back to record